AMR Bio launches as clinical-phase biotech to advance Phase III-ready topical antimicrobial XF-73
The firm has announced its launch as a clinical-stage biotechnology company focused on advancing XF-73 Nasal, a first-in-class topical gel, towards Phase III development and commercialisation as a pre-surgical decolonisation treatment